BR112016017087A8 - forma cristalina alfa do composto monobenzoato a e seu método de preparação e composição farmacêutica compreendendo-a - Google Patents

forma cristalina alfa do composto monobenzoato a e seu método de preparação e composição farmacêutica compreendendo-a Download PDF

Info

Publication number
BR112016017087A8
BR112016017087A8 BR112016017087A BR112016017087A BR112016017087A8 BR 112016017087 A8 BR112016017087 A8 BR 112016017087A8 BR 112016017087 A BR112016017087 A BR 112016017087A BR 112016017087 A BR112016017087 A BR 112016017087A BR 112016017087 A8 BR112016017087 A8 BR 112016017087A8
Authority
BR
Brazil
Prior art keywords
crystalline form
monobenzoate
compound
preparation
pharmaceutical composition
Prior art date
Application number
BR112016017087A
Other languages
English (en)
Other versions
BR112016017087B1 (pt
BR112016017087A2 (pt
Inventor
Tan Songde
Li Tongshuang
Wang Weibo
Original Assignee
Shanghai Fochon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fochon Pharmaceutical Co Ltd filed Critical Shanghai Fochon Pharmaceutical Co Ltd
Publication of BR112016017087A2 publication Critical patent/BR112016017087A2/pt
Publication of BR112016017087A8 publication Critical patent/BR112016017087A8/pt
Publication of BR112016017087B1 publication Critical patent/BR112016017087B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

the present invention relates to the field of preparing pharmaceutical compounds, in particular relates to a crystalline form a of compound a monobenzoate, which is a dpp-iv inhibitor, and a preparation method thereof, and a pharmaceutical composition comprising the crystalline form.
BR112016017087-3A 2014-01-24 2015-01-26 Forma cristalina alfa do composto monobenzoato a, seu método de preparação, e composição farmacêutica BR112016017087B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410037009 2014-01-24
CN201410037009.X 2014-01-24
PCT/CN2015/071525 WO2015110077A1 (zh) 2014-01-24 2015-01-26 化合物A单苯甲酸盐的晶型α及其制备方法和含有该晶型的药物组合物

Publications (3)

Publication Number Publication Date
BR112016017087A2 BR112016017087A2 (pt) 2017-08-08
BR112016017087A8 true BR112016017087A8 (pt) 2018-04-17
BR112016017087B1 BR112016017087B1 (pt) 2022-12-27

Family

ID=53680849

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016017087-3A BR112016017087B1 (pt) 2014-01-24 2015-01-26 Forma cristalina alfa do composto monobenzoato a, seu método de preparação, e composição farmacêutica

Country Status (5)

Country Link
CN (1) CN104803971B (pt)
BR (1) BR112016017087B1 (pt)
MX (1) MX366651B (pt)
RU (1) RU2677660C2 (pt)
WO (1) WO2015110077A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106349215B (zh) * 2015-07-15 2022-02-08 深圳信立泰药业股份有限公司 一种化合物a苯甲酸盐的无定形及其制备方法和含有该无定形的药物组合物
CN106349216B (zh) * 2015-07-15 2020-09-11 深圳信立泰药业股份有限公司 化合物A的晶型α及其制备方法和含有该晶型的药物组合物
WO2018219295A1 (zh) * 2017-05-31 2018-12-06 深圳信立泰药业股份有限公司 二肽基肽酶iv抑制剂的氘代1,2,4-三嗪衍生物
CN109692164A (zh) * 2017-10-20 2019-04-30 深圳信立泰药业股份有限公司 化合物a或其盐的药物组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2805953B1 (en) * 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
CA2622642C (en) * 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
FR2933979B1 (fr) * 2008-07-15 2012-08-24 Pf Medicament Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
CN102791701B (zh) * 2009-12-30 2014-02-12 深圳信立泰药业股份有限公司 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
BR112012028906A2 (pt) * 2010-05-12 2016-07-26 Mapi Pharma Ltd polimorfos de benzoato de alogliptina
CN103172615A (zh) * 2013-03-29 2013-06-26 山东罗欣药业股份有限公司 苯甲酸阿格列汀晶型化合物

Also Published As

Publication number Publication date
BR112016017087B1 (pt) 2022-12-27
BR112016017087A2 (pt) 2017-08-08
CN104803971A (zh) 2015-07-29
WO2015110077A1 (zh) 2015-07-30
MX366651B (es) 2019-07-17
RU2677660C2 (ru) 2019-01-18
RU2016134404A (ru) 2018-03-01
MX2016009667A (es) 2017-02-28
RU2016134404A3 (pt) 2018-08-15
CN104803971B (zh) 2021-11-30

Similar Documents

Publication Publication Date Title
TWI560185B (en) Acid addition salt of trk inhibitor compound
DK3369425T3 (da) Sammensætninger omfattende bakteriestammer
DK3650033T3 (da) Sammensætninger omfattende bakteriestammer
IL247923A0 (en) 4-substituted nucleotide derivatives as HIV reverse transcriptase inhibitors
BR112017004612A2 (pt) compostos, composição farmacêutica, usos de um composto, e kit
EA201692219A1 (ru) Способы получения противовирусных соединений
PE20160862A1 (es) Polimorfo de los inhibidores de la syk
MX2017008442A (es) Uso de picolinamidas como fungicidas.
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
HUE053463T2 (hu) Pirrolopirimidin vegyületek, amelyek használhatók JAK inhibitorokként
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
NZ732402A (en) Nitrification inhibitor compositions and methods for preparing the same
EA201691363A1 (ru) Стабилизированные силикатные композиции и их применение в качестве антиперспирантных композиций
BR112017008481A2 (pt) composto antimicótico
MX2015014688A (es) Tiazoles y usos de los mismos.
DK3137437T3 (da) Mikroindkapslet nitrifikationsinhibitorsammensætning
DK3240767T3 (da) Mikroindkapslede nitrifikationshæmmersammensætninger
BR112016017776A8 (pt) forma cristalina ou forma sólida de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidróxi-4-metil-ciclo-hexilamino)-pirimidina-5-carboxamida, método de preparo, método de purificação, composto, composição farmacêutica e uso de forma cristalina ou forma sólida
MX2017003550A (es) Uso de cisteamina en tratamiento de infecciones causadas por levaduras/mohos.
EP3176173A4 (en) Crystalline free bases of c-met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof
BR112016017087A8 (pt) forma cristalina alfa do composto monobenzoato a e seu método de preparação e composição farmacêutica compreendendo-a
ZA201700518B (en) Use of active compound compositions
DK3119198T3 (da) Semiokemiske sammensætninger til at reducere sociale konflikter med katte
CL2016003144A1 (es) Método y composición para mejorar la productividad de plantas no leguminosas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/01/2015, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: FOCHON PHARMACEUTICALS, LTD. (CN)